Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases took place in Copenhagen, Denmark, from 17-21 March, 2026. This conference showcased the latest advances in treatment, translational research, and clinical trials across Alzheimer’s, Parkinson’s, and related neurological disorders. For more content from AD/PD, check out our dementia journal here.

AD/PD 2026

AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases
17–21 March 2026 | Copenhagen, Denmark

AD/PD 2026

AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases
17–21 March 2026 | Copenhagen, Denmark
The AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases took place in Copenhagen, Denmark, from 17-21 March, 2026. This conference showcased the latest advances in treatment, translational research, and clinical trials across Alzheimer’s, Parkinson’s, and related neurological disorders. For more content from AD/PD, check out our dementia journal here.
Repurposing ambroxol for the treatment of synucleinopathies 2:41
Repurposing ambroxol for the treatment of synucleinopathies
Stephen Pasternak • 16 Mar 2026
Phase II trial insights on ambroxol in Parkinson’s disease dementia 5:11
Phase II trial insights on ambroxol in Parkinson’s disease dementia
Stephen Pasternak • 16 Mar 2026
The development of a novel blood-based biomarker for early detection of Parkinson’s disease 4:53
The development of a novel blood-based biomarker for early detection of Parkinson’s disease
Hermona Soreq • 9 Mar 2026
The clinical utility of second-generation tau PET tracers in neurodegenerative diseases 1:55
The clinical utility of second-generation tau PET tracers in neurodegenerative diseases
Saul Martinez-Horta • 20 Mar 2026
The PI‑2620 tau-PET tracer to detect tau pathology or co-pathology in neurodegenerative diseases 1:26
The PI‑2620 tau-PET tracer to detect tau pathology or co-pathology in neurodegenerative diseases
Saul Martinez-Horta • 20 Mar 2026
Immersive virtual reality and adaptive cognitive training PD with MCI: the CogMusT trial 3:56
Immersive virtual reality and adaptive cognitive training PD with MCI: the CogMusT trial
Saul Martinez-Horta • 20 Mar 2026
Assessing cognition in Huntington’s disease: the potential of the PDCRS 2:03
Assessing cognition in Huntington’s disease: the potential of the PDCRS
Saul Martinez-Horta • 20 Mar 2026
A study using tau PET tracer reveals associations between tau pathology and clinical symptoms in HD 3:13
A study using tau PET tracer reveals associations between tau pathology and clinical symptoms in HD
Saul Martinez-Horta • 20 Mar 2026
The spectrum of alpha-synuclein species in Parkinson’s disease and other synucleinopathies 2:09
The spectrum of alpha-synuclein species in Parkinson’s disease and other synucleinopathies
Tiago Outeiro • 19 Mar 2026
The link between diabetes and PD and the potential targeting of shared pathways 1:07
The link between diabetes and PD and the potential targeting of shared pathways
Tiago Outeiro • 19 Mar 2026
Unanswered questions in alpha-synuclein biology 1:21
Unanswered questions in alpha-synuclein biology
Tiago Outeiro • 19 Mar 2026
Novel synuclein mutations and their potential impact in Parkinson’s disease 2:46
Novel synuclein mutations and their potential impact in Parkinson’s disease
Tiago Outeiro • 19 Mar 2026
The limitations of currently approved treatments for Parkinson’s disease 1:15
The limitations of currently approved treatments for Parkinson’s disease
Fabrizio Stocchi • 20 Mar 2026
An overview of current trials investigating novel approaches for the treatment of PD 2:37
An overview of current trials investigating novel approaches for the treatment of PD
Fabrizio Stocchi • 20 Mar 2026
Advice for referring patients with Parkinson’s disease for advanced therapies 1:38
Advice for referring patients with Parkinson’s disease for advanced therapies
Fabrizio Stocchi • 20 Mar 2026
Factors contributing to neurodegeneration in PD and strategies being explored for prevention 2:33
Factors contributing to neurodegeneration in PD and strategies being explored for prevention
Fabrizio Stocchi • 20 Mar 2026
The content of VJNeurology is intended for healthcare professionals